Drug Trial Radar · NCT04463017
Ascending Dose Study of HU6 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: May 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Aug 12, 2020
Primary completion
Mar 30, 2021
Study completion Apr 1, 2021
Sponsor
- Lead sponsor
- Rivus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single ascending dose trial in healthy volunteers. The study will be conducted in up to 7 cohorts. Upon review of the safety and PK data, it may be decided to expand the current cohort versus dose escalate to the next cohort. In addition, the sponsor may elect not to enroll all 7 cohorts based on safety and/or PK and/or PD data.
Conditions
- NASH - Nonalcoholic Steatohepatitis
Interventions
HU6Drug
HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the dose relationship of PK Parameter CmaxTime frame: 3 months
- Assess the dose relationship of PK Parameter AUCTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prism Clinical Research
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.